에서 실시간으로 운영 중이에요! 자세히 알아보기

Ashland

ASH

시가총액 US$32.6억

71.15 USD

-0.44

0.61%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

71.15

0.00

0%

1일

-0.61%

5일

1.41%

1개월

0.95%

3개월

3.4%

6개월

23.8%

연초 이후

18.88%

1년

45.38%

5년

-25.99%

10년

28.08%

소개: Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.

직원 수: 2,900

소재 특수화학물질

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 35%

중립 60%

부정적 5%

Zacks Investment Research

ASH's Shares Rally 30% in 6 Months: What's Driving the Upside?

Ashland's shares have gained 30.2% in six months as cost cuts, portfolio optimization and a $1-billion buyback support returns.

ASH's Shares Rally 30% in 6 Months: What's Driving the Upside?

Ashland scales Transformed Vegetable Oils technology platform in crop care, launches agrimer™ eco-disperse OD polymeric dispersant

WILMINGTON, Del., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Continuing to scale its Transformed Vegetable Oils (TVO™) technology platform, Ashland Inc. (NYSE: ASH), today announced the global launch of agrimer™ eco-disperse OD TVO™ polymeric dispersant, a patented, nature-based dispersant developed for non-aqueous crop protection formulations.

Ashland scales Transformed Vegetable Oils technology platform in crop care, launches agrimer™ eco-disperse OD polymeric dispersant

Ashland Inc. (ASH) Analyst/Investor Day Transcript

Ashland Inc. (ASH) Analyst/Investor Day Transcript

Ashland Inc. (ASH) Analyst/Investor Day Transcript

Zacks Investment Research

Here's Why You Should Retain ASH Stock in Your Portfolio Now

Ashland is using cost savings, portfolio optimization and buybacks to strengthen margins and free cash flow despite tariff and demand headwinds.

Here's Why You Should Retain ASH Stock in Your Portfolio Now

Ashland Innovation Day to be held September 17, 2026

Wilmington, Del., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host an Innovation Day webcast on September 17, 2026.

Ashland Innovation Day to be held September 17, 2026

Ashland to host Innovation Day for analysts and investors

Wilmington, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a live Innovation Day webcast for analysts and investors from Wilmington, Delaware on September 17, 2026. The event will provide an updated view of Ashland's Technology Platforms, including their commercial progress and scalability. Registration is required and can be accessed from the following link: innovationday26.ashland.com

Ashland to host Innovation Day for analysts and investors

Zacks Investment Research

Ashland (ASH) Up 2% Since Last Earnings Report: Can It Continue?

Ashland (ASH) reported earnings 30 days ago. What's next for the stock?

Ashland (ASH) Up 2% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

ASH Launches Permexa Sodium Caprate to Support Oral Biologics Growth

Ashland launches Permexa sodium caprate to support oral peptide and biologic development with enhanced processing and permeability.

ASH Launches Permexa Sodium Caprate to Support Oral Biologics Growth

Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate

WILMINGTON, Del., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), is announcing the launch of permexa™ sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.

Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate

Ashland Inc.: Activist Pressure Starts To Pay Off

Ashland Inc. (ASH) remains a Buy, with the investment case now centered on activist-driven M&A potential and strategic alternatives. Life Sciences and Personal Care segments, comprising 82% of gross EBITDA, continue to deliver growth and margin stability, underpinning valuation. Multiple activist investors, including Standard Industries and Ancora, have driven board changes, capital allocation reviews, and engagement with potential acquirers.

Ashland Inc.: Activist Pressure Starts To Pay Off

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.